Skip to main content
. 2020 Feb 13;26:102210. doi: 10.1016/j.nicl.2020.102210

Table 1.

Demographics and clinical variables for the FTD patient groups and controls, together with basal forebrain volumes. Values denote means (standard deviation) or n (%). Mean volumes in bold denote significant p-values in comparison to controls once adjusting for multiple comparisons.

Groups n Gender, male Age at scan (years) Disease duration (years) Basal forebrain volume as % of TIV p-value
Controls 83 45 (54%) 63.4 (10.8) 0.071 (0.007)
Clinical bvFTD 148 103 (70%) 61.5 (8.2) 5.1 3.3) 0.066 (0.008) <0.0005
nfvPPA 103 49 (48%) 68.4 (8.5) 4.3 (2.2) 0.068 (0.007) <0.0005
svPPA 82 46 (56%) 63.8 (7.3) 4.8 (2.5) 0.065 (0.007) <0.0005
PPA-NOS 14 10 (71%) 63.9 (6.2) 3.3 (1.7) 0.067 (0.006) 0.005
FTD–MND 9 5 (56%) 65.3 (4.1) 4.5 (2.4) 0.066 (0.007) 0.010
Genetic C9orf72 26 17 (65%) 61.6 (7.0) 5.5 (3.3) 0.072 (0.007) 0.857
GRN 15 7 (47%) 62.6 (6.7) 2.9 (2.7) 0.069 (0.006) 0.107
MAPT 24 15 (63%) 55.4 (7.0) 5.7 (3.2) 0.059 (0.008) <0.0005
Pathological TDP-43 35 21 (60%) 63.3 (7.9) 4.3 (2.5) 0.068 (0.006) 0.003
TDP-A 12 6 (50%) 61.6 (8.2) 3.1 (1.6) 0.069 (0.005) 0.133
TDP-B 2 1 (50%) 55.0 (9.4) 5.0 (3.7) 0.077 (0.009) 0.403
TDP-C 21 14 (67%) 65.1 (7.3) 4.9 (2.7) 0.066 (0.005) 0.001
Tau 28 21 (72%) 61.8 (9.7) 4.7 (2.3) 0.065 (0.007) <0.0005
Pick's disease 11 8 (73%) 61.3 (2.5) 4.2 (2.0) 0.063 (0.006) <0.0005
FTDP-17 6 4 (67%) 52.4 (6.2) 5.8 (3.1) 0.060 (0.009) <0.0005
CBD 7 5 (71%) 59.5 (9.0) 4.5 (0.9) 0.071 (0.006) 0.609
PSP 4 4 (100%) 76.9 (7.3) 5.1 (3.9) 0.064 (0.003) 0.030
FUS 3 2 (67%) 43.9 (13.6) 3.3 (2.1) 0.066 (0.008) 0.172